Abstract: There is a clear unmet medical need for new pharmacologic therapies for the treatment of atrial fibrillation (AF) with improved efficacy and safety. This article reviews the development of new and novel Kv1.5/ultra-rapid delayed-rectifier current (I Kur ) inhibitors and presents evidence that Kv1.5 modulation provides an atrial-selective mechanism for treating AF. Academia and industry have invested heavily in Kv1.5 (.500 scientific publications and .50 patents published since 1993); however, to realize the full value of this therapeutic drug target, clinical efficacy and safety data are required for a selective Kv1.5 modulator. The reward for demonstrating clinical efficacy and safety in a pivotal Phase 3 trial, on regulatory approval, is ''first in class'' status.
INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia facing physicians, afflicting 13% of men and 11% of women older than 85 years of age. 1, 2 With recent epidemiologic studies estimating that there are more than 11 million people with AF in the 7 major economies [2] [3] [4] [5] at an estimated cost of $3600 per patient per year, 6 the global economic burden of AF is significant. Increased life expectancy (eg, improved treatments for cardiovascular disease and stroke), the development of cardiac monitoring techniques capable of detecting paroxysmal (infrequent self-terminating) AF and asymptomatic AF, and a change in the definition of AF that now includes secondary AF have contributed to an increase in the prevalence of AF. 5 The prevalence of AF is predicted to increase 2-to 3-fold in the United States from 2005 to 2050 and cause a further increase in the associated financial burden. 3 AF is clinically significant because it contributes to the incidence of heart failure and stroke and also to overall cardiovascular morbidity and mortality. Data from the Framingham Heart Study show that AF is associated with a 1.5-to 1.9-fold higher risk of death, much of which results from thromboembolic stroke. 7 Patients with AF have a 5-fold increased risk for stroke; indeed, in the United States approximately 15% to 25% of all strokes can be attributed to AF. 8 This figure will increase if the ongoing ASSERT (ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial) study confirms a relationship between asymptomatic AF and stroke. 9 In addition to stroke, AF is implicated in hemodynamic dysfunction, tachycardia-induced cardiomyopathy, and systemic embolism, and all have a substantial impact on quality of life.
The etiology of AF is complex; AF can be triggered by ectopic activity, single-circuit reentry, or multiple circuit reentry. 10 Current strategies for the control of AF involve either sinus rhythm (SR) maintenance or heart rate control. Although there is a consensus among cardiologists that SR control is the preferred and most effective treatment of AF, none of the SR control drugs currently available are able to maintain rhythm without significant negative side effects. 11, 12 For example, the available agent that is most effective, amiodarone, causes serious adverse effects including pulmonary toxicity (1%-17%), corneal microdeposits (.90%), optic neuropathy/neuritis (1%-2%), blue-grey skin discoloration (4%-9%), photosensitivity (25%-75%), hypothyroidism (6%), hyperthyroidism (0.9%-2%), peripheral neuropathy (0.3%), and hepatotoxicity (15%-30%). 13 Class Ia antiarrhythmics (eg, quinidine) are associated with torsade de pointes (TdP) 14 ; Class Ic antiarrhythmics (eg, flecainide) increase mortality in patients with ischemic and structural heart disease 14 ; and all of the currently used Class III antiarrhythmic agents lack atrial specificity and therefore may possess a highly undesirable proarrhythmic liability in the ventricles, which can lead to TdP and sudden cardiac death. 15 Thus, there is a clear unmet medical need for new pharmacologic AF therapy with improved efficacy and safety. 1 To address this unmet medical need, the pharmaceutical industry is searching for novel atrial-selective antiarrhythmic agents with a much improved efficacy and safety profile. 16 An emerging putative atrial-selective drug target is Kv1. 5 , which has been shown to underlie the cardiac ultra-rapid delayedrectifier (I Kur ) current in humans [17] [18] [19] and, importantly, displays atrial-specific expression in the heart. [20] [21] [22] Therefore, selective Kv1.5 blockers are thought to represent a safer pharmacologic intervention strategy for pharmacologic cardioversion of AF and the prevention of recurrence of AF when compared with existing Class III antiarrhythmics. In addition to antiarrhythmic activity, Kv1.5 blockers may also improve atrial contractility and reduce thromboembolic risk. 23, 24 Kv1.5 has been the focus of intense research by academia and industry alike, with .500 scientific publications and .50 patents published since 1993; See Figure 1 . This article reviews the development of new and novel small molecule Kv1.5 inhibitors by a number of companies over the last decade. Compounds are grouped according to company and chemical class, and evidence for their potential value for treating AF is discussed. New compounds that preferentially block Kv1.5 at therapeutically relevant doses are included in this review. To focus this review, compounds for which only Kv1.5 current inhibition data exist are not covered in detail (Table 1) . Peerreviewed publications (full papers and scientific abstracts), patents, and company information (press releases, annual reports, Web sites) provided the content for this review. It should be noted that the claims of patents and company literature are not subject to the rigors of expert peer review.
Animal models are essential tools in the investigation and development of drug therapies for AF and atrial flutter (AFL). A number of species and models have been used. It is important that the model represents the human condition to as great an extent as is possible or is at least predictive of efficacy in man. A number of species have been used to investigate the efficacy of I Kur blockers in the prevention or termination of AF. Similar to man [17] [18] [19] 25 Kv1.5 is the molecular correlate of I Kur in the dog, [26] [27] [28] [29] pig, 30 and rat 27, 31 and plays an important functional role in repolarization in the atria. In other species the molecular physiology of repolarization of the atria is less well understood. Studies have shown Kv1.5 ribonucleic acid is highly expressed in the rabbit, 32 goat, 33 and African green monkey 34 atria, and protein expression has been reported in the atria and sinoatrial node of ferret and guinea pig atria. 35 However, electrophysiologic data to support a functional role of Kv1.5/I Kur in repolarization of these species are lacking. The most commonly used large species are dog, goat, and pig. Kv1.5 messenger ribonucleic acid (mRNA) and protein have been detected in canine atrial and ventricular tissue and are reported to be the molecular correlate of I Kur in dog atrial 26 and ventricular 36 myocytes. Thus, although dog is a relevant species for AF efficacy studies, Kv1.5 inhibitors may increase the ventricular effective refractory period (VERP) and heart rate corrected QT interval (QTc) interval in dogs. It is important to note that I Kur has not been detected in human ventricular myocytes and therefore the same observation is unlikely in man. This is supported by the observation that 1 mM diphenylphosphine oxide (DPO-1), a specific Kv1.5 blocker, has less of an effect on action potential duration (APD) recorded from human ventricular tissue 37 compared with APDs recorded from canine ventricular myocytes. 36 Rodent models should be used with caution because, unlike larger animals, 38 the transient-outward potassium current (I to ) contributes to late (Phase 3) repolarization and APD 39 and as such this species is unlikely to differentiate Kv4.2/3 from Kv1.5 blockers. The lack of human clinical data for selective Kv1.5 blockers means no conclusion can be drawn regarding which animal model is most predictive. Aventis Pharma/Sanofi-Aventis
Aventis Pharma/Sanofi-Aventis has developed several novel nonselective Kv1.5 inhibitors from multiple chemically distinct series that include bisaryls, anthranilic acids, pyrrolidin-2-ones, piperidin-2-ones, and isothiazolidine-1,1-dioxides. Although many of the agents reported by Aventis Pharma/ Sanofi-Aventis are mixed ion channel blockers, atrial selectivity and efficacy have been demonstrated in vivo. The atrial selective mechanism of action presumably stems from the compounds' propensity to block currents expressed solely or predominantly within the atria [ie, I Kur (cardiac ultra-rapid delayed-rectifier potassium current), I to and I K(ACh) (cardiac acetylcholinemodulated inward rectifier potassium current)] 40,41 independent of I Kr (cardiac rapid delayed rectifier potassium current) modulation. [42] [43] [44] AVE0118 and AVE1231 have entered clinical development for the treatment of AF.
Bisaryls
AVE0118 inhibits hKv1.5 with an IC 50 of 1.1 mM.
45
AVE0118 inhibits hKv1.3, hKv2.1, hKv3.1, and hKv4.3 ion channels and pig atrial I K(ACh) with broadly similar potency to hKv1.5 45, 46 and displays a modest 10-fold selectivity over the cloned hERG (human ether-a-go-go related gene) channel (IC 50 ;10mM). Good selectivity for Kv1.5 is demonstrated over other native cardiac currents I K1 (cardiac inward rectifier potassium current), I Ks (cardiac slow delayed-rectifier potassium current), I K(ATP) (cardiac adenosine triphosphatemodulated inward rectifier potassium current), I CaL (cardiac L-type calcium current) 24, 45 (Table 2 ). In vitro, AVE0118 (6 mM) elevated the atrial action potential (AP) plateau and prolonged APD in human atrial tissue from patients with AF, 47 with higher concentrations (10-30 mM) producing a positive inotropic effect in human atrial tissue from patients with SR 81 and AF. 24 Similarly, AVE0118 prolonged APD 30 and elevated the plateau potential in canine right atrial (RA) myocytes at concentrations of 1-100 mM while shortening APD 50 and ADPD 90 in right ventricular (RV) myocytes. The effect of AVE0118 on human ventricular action potential profile in vitro has not been reported. In Langendorff-perfused rabbit hearts where the right atrium was dilated to shorten the atrial effective refractory period (AERP) and increase AF vulnerability, AVE0118 at the maximum dose (10 mM) prolonged right AERP (RAERP) by 85%. Perfusion of the same concentration reduced AF vulnerability to 0 and in a separate group terminated sustained AF in 5/6 hearts to SR by reducing the signal complexity. 48 Thus, in vitro at 1-to 10-fold above the IC 50 for Kv1.5, AVE0118 delays atrial but not ventricular repolarization and is able to prevent and terminate AF.
The in vivo electrophysiologic effects and antiarrhythmic properties of AVE0118 have been well-characterized in a number of animal models (Table 3 ). In the anesthetized pig, intravenous administration of 1 mg/kg AVE0118 preferentially increased the LAERP (left AERP) . RAERP (56% versus 20% at 3.3Hz) and completely prevented left atrial vulnerability (LAV) to extrastimulus-induced AF. 44, 49 At this dose AVE0118 had no effect on QT/QT c interval. 49 In contrast, I Kr blockers preferentially prolonged RAERP . LAERP and the QTc interval and failed to reduce LAV. 43, 44 Thus, it is clear that AVE0118 has a different mechanism of action to I Kr blockers. In a conscious goat pacing-induced tachycardia model of persistent AF, intravenous administration of 3 mg/kg AVE0118 was more effective in increasing the AERP in AF animals (.35%-50%) compared with control animals (.10%-30%) and reduced AF vulnerability by 68%. 50 Furthermore, intravenous administration of 5 mg/kg AVE0118 (peak plasma concentration 10.22 mM) terminated persistent AF in 5/8 goats and had no effect on the QT interval or atrial conduction velocity. 50 As in human atrial tissue, AVE0118 was able to restore atrial contractility following cardioversion in the goat persistent AF model. 23 An increase in atrial contractility may increase the blood flow velocity in the left atrium (LA) following cardioversion, resulting in lower risk of thrombus formation and stroke, and it may be a Kv1.5 blocker ''class effect.'' 23, 51 In the canine chronic complete AV block (CAVB) model, in which animals are susceptible to TdP, a range of AVE0118 doses producing plasma concentrations that reached 12.7 mM did not increase the QTc interval, cause TdP, or prevent dofetilide-induced TdP. 52 Complementary to the in vitro data, AVE0118 selectively increases the AERP with minimal effects on ventricular function.
AVE0118 is poorly soluble, 48, 49 undergoes rapid firstpass hepatic metabolism, 53 and has a short half-life in dog and pig (intravenous administration, T 1/2 = 0.2-0.4 hours 52, 54 ). AVE0118 has not progressed past Phase 2 clinical development for AF 55 and is currently in preclinical development for obstructive sleep apnea via a nasal route. 56 No Phase 2 clinical data for AVE0118 have been published to date. S9947 inhibits hKv1.5 (IC 50 value 417 nM), in a strong positive frequency-dependent manner and also inhibits human I Kur (IC 50 value 77 nM) 57, 58 (Table 2 ). S9947 does not inhibit hERG heterologously expressed in oocytes at 10 mM. Similar to AVE0118, S9947 (intravenous administration at 1 and 3 mg/kg) preferentially increased LAERP (;20%-55% LAERP and 10%-15% RAERP) and abolished LA vulnerability at the higher dose in the anesthetized pig without prolonging the QTc interval. 43, 44 Pharmacokinetic properties, efficacy in AF models, and the development status of S9947 are unknown. Similar observations in pig were also reported for the Kv1.5 blocker S20951. 43, 44 Anthranilic Acids AVE1231, an anthranilic acid (structure not disclosed), blocked hKv1.5 and I Kur , I to and I K(ACh) with IC 50 values of 3.6, 0.9, 3.3, and 8.4 mM, respectively; displayed superior hERG selectivity to AVE0118 (IC 50 ;30 mM; see Table 2 ); and had no effect on guinea pig papillary muscle APD 90 at 30 mM.
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At the maximum-studied oral dose in the anesthetized pig, AVE1231 (3 mg/kg) produced a 30% increase in LAERP at the fastest pacing rate and reduced LAV by 86% with no effect on the QT/QTc, R-R intervals or the QRS complex. 54 An almost identical effect was observed following intravenous administration in the anesthetized pig at 3 mg/kg. 54, 59 In a conscious pacinginduced tachycardia goat model of persistent AF, intravenous administration of 3 mg/kg AVE1231 was more effective in increasing the AERP in AF animals (;40%) compared with control animals (;27%) and had no effect on the QTc interval. 42, 54 However, in contrast to AVE0118, AVE1231 was less effective in reducing LAV following remodeling and did not increase the LAERP in a reverse-rate-dependent fashion in this goat model. 42 Unlike AVE0118, AVE1231 was shown to be orally active in the pig model. 54 AVE1231 is currently in Phase 1.
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AVE3295 (structure not disclosed) inhibits pig I Kur , I to and I K(ACh) with a IC 50 s of 0.3, 0.5, and 2.4 mM, respectively 59 ( Table 2) . Although a more potent ion channel blocker than the structurally similar AVE1231, AVE3295 was less effective in vivo, producing smaller changes in anesthetized pig LAERP and LAV at an identical dose (Table 3) . 59 At 3 mg/kg intravenous AVE3295 produced no significant effect on the pig QT interval.
S0100176 (Compound 3i   60 ) is a positive frequencydependent open channel blocker of hKv1.5 (IC 50 value 700 nM in oocytes), .10-fold selective for hERG (see Table 2 ), and orally bioavailable (43%) in the rat. 60, 61 No in vivo electrophysiology has been published for this compound and its development status is unknown.
The Aventis (nonselective) Kv1.5 inhibitors previously mentioned appear to have a ''class effect'' independent of I Kr modulation. Preferential action on the LAERP and efficacy in animal models support the possibility of Kv1.5 inhibitors as effective in both the prevention and termination of AF without producing undesirable ventricular effects. Table 2 ). Although all 3 ion channels are expressed in the human atria, the pharmacodynamic benefit of modulating these 3 ion channels is unknown because no AF efficacy data have been presented. It was noted that the TASK-1 modulating activity of these compounds may be mechanistically important in several other noncardiac diseases (eg, sleep apnea). 62 
Cardiome/Astellas Pharma
Vernakalant hydrochloride (RSD1235) developed by Cardiome (later Astellas) inhibits hKv1.5 and human I Kur in a use-and frequency-independent fashion with an IC 50 of 13 mM (0.25-20 Hz) and 9 mM (0.1-3Hz), respectively. 63, 64 However, at depolarized resting membrane potentials and high frequencies vernakalant preferentially inhibits hNav1.5 64 and I to (Table 2) 63,64 over hKv1.5. A mechanism for chamber selectivity of the Na + channel blockers, ranolazine and lidocaine, has been proposed to be consequent on different Na + channel inactivation characteristics in, respectively, the atria and the ventricles 65 and this may in part explain vernakalant's atrial selectivity. As a preferential Na + channel blocker, vernakalant is outside the remit of this review 66 ; however, it is noteworthy because in December 2007 a U.S. Food and Drug Administration expert advisory panel recommended approval of vernakalant (Kynapid) for rapid cardioversion of recent-onset AF.
Imadazo Derivatives
Compound 1 is a modest inhibitor of hKv1.5 (IC 50 value 4.8 mM) that is selective for hKv1.5 over several nontarget cardiac currents: hERG (20-fold), Kv4.2 (7-fold), Kv2.1 (12-fold), and Nav1.5 (;60-fold). 67 Intravenous administration of 2.5 and 10 mg/kg Compound 1 marginally reduced AF duration (;40%) and increased the AERP (10%) in the dog pacing-induced AF model. In another study, Compound 1 did not significantly increase the pulmonary artery pressure at 25 mg/kg in rat, suggesting that, in contradiction to previously reported studies, Kv1.5 is not functionally important in pulmonary artery smooth muscle cells.
68 C9356 (structure and chemical series undisclosed) is a Kv1.5 blocking compound that displays identical pharmacology to Compound 1 ( Table 2) . 26 It is unclear if Cardiome is actively pursuing Kv1.5 as a target for AF.
Icagen/Eli Lilly/Bristol-Myers Squibb
In separate collaborations with Eli Lilly and BristolMyers Squibb (BMS), Icagen has developed several novel Kv1.5 inhibitors from multiple distinct chemical series that include indanes, tetralins, benzocycloheptanes, thiazolidinones, metathiazanones, and dihydropyrimidines (see Tables  2 and 3 for key compound examples). A clinical development candidate was identified by the Icagen-BMS program and progressed to a Phase 1 proof-of-concept trial. However, in December 2005 Icagen/BMS announced discontinuation of the trial because of slow enrollment. It has also been reported that clinical trials of exemplified Compound 25 69 were halted because of poor solubility and oral bioavailability. 70 It is unclear if these 2 trials are one and the same.
Indanes
In 1998 Icagen and Eli Lilly published work relating to a series of indane compounds. Compound 4 (ICAGEN- 4 71 ) is an open channel, frequency-dependent inhibitor of hKv1.5, blocking the hKv1.5 current and human I Kur with IC 50 s of 100-160 nM and 1 mM, respectively, and capable of prolonging the human atrial APD in vitro at 1 mM. 58, 71, 72 This compound was shown to inhibit human T-cell proliferation at 10 mM as a result of off-target activity through Kv1.3. 71 Further Icagen patents have expanded on the indane series revealing compounds that inhibit hKv1.5 current by 20% to 66% at 100 nM. 69, 73 Using ICAGEN-4 as a template, Icagen and BMS have produced a collection of aryl sulphonamido indanes with potency against hKv1.5 ranging from 33 to 880 nM. 72 The most potent compound (1R,2R diastereomer of ICAGEN-4) displayed good selectivity over hERG, hNav1.5, and rat pituitary Ca 2+ current (Table 2 ) but was not orally bioavailable in the rat and dog. Improved solubility and pharmacokinetic profiles would be required to allow these compounds to progress to the clinic.
Benzopyrans
BMS replaced the indane scaffold (ICAGEN-4 71 ) with a benzopyran scaffold yielding compounds with an IC 50 s for hKv1.5 ranging from 57 nM to .1 mM and excellent selectivity over hERG (100-300-fold) 74 (Compound 9a, Table 2 ). No in vivo electrophysiology has been published for these compounds and their development status is unknown.
Tetrahydronaphthalenes
In 2002 Icagen published 2 patents detailing compounds that potently inhibit both the peak and the steady-state hKv1.5 current at 100 nM. AP voltage-clamp studies using a human atrial AP waveform applied to hKv1.5-expressing cells showed that compounds with a ''slow-off rate'' (those that inhibited peak hKv1.5 current) were more effective in blocking the hKv1.5 current during the human atrial AP waveform and thus were predicted to be more effective antiarrhythmics. 75, 76 However, no in vivo data are presented to support this hypothesis. From the data presented it is unclear if the compounds have a slow off rate or very rapid on rate.
Because very little in vivo data are available for the Icagen/Eli Lilly/BMS compounds described previously, it is difficult to determine the development status of their Kv1.5 inhibitor programs.
Merck
Merck has developed several novel Kv1.5 inhibitors from multiple distinct chemical series that include diphenyphosphine oxides, isoquinolinones, triarylethanolamines, and diisopropylamides. It is not known if Merck has selected a development candidate from 1 of these chemical series.
Diphenylphosphine Oxides
DPO-1, a potent frequency-dependent inhibitor of hKv1.5 (IC 50 value 30 nM) and human I Kur (IC 50 value 30 nM), 37 is selective for Kv1.5/I Kur over several nontarget cardiac currents: I to (8-fold), I K1 (20-fold), I Kr (20-fold), and I Ks (20-fold). 37 An atrial-selective mechanism has been demonstrated ex vivo; DPO-1 (at 1 mM) increased the duration of APs recorded from dissociated human atrial myocytes (increases APD 50 by 120% and APD 90 by 25%) and had no effect on the duration of APs recorded from ventricular myocytes. 37 The in vivo cardiac electrophysiologic profile of DPO-1 has been reported for rat and African green monkey: DPO-1 at 12 mg/ kg (plasma concentration ;8 mM) increased the AERP and VERP by 42% and 64%, respectively, in rat; and at 10 mg/kg (plasma concentration 5 mM) selectively increased the AERP by 15% in monkey. 77 DPO-1 terminated atrial flutter in 6/6 dogs at a mean intravenous dose of 5.5 mg/kg 6 2 mg/kg and selectively increased the AERP by 15%. 78 Mean pharmacodynamic and pharmacokinetic data were not reported for individual dose groups; however, in the example that was cited, DPO-1 terminated AFl at 10 mg/kg but not at 1 and 3 mg/kg. Although atrial selectivity and antiarrhythmic activity have been demonstrated, DPO-1 is unlikely to enter drug development if it is not orally bioavailable (only intravenous data have been reported). DPO-1's pharmacology and pharmacodynamic effects are also reported elsewhere.
79,80

Isoquinoline-3-Nitriles
Limited electrophysiology and pharmacokinetic data are available for isoquinoline-3-nitrile (ISQ-1; hKv1.5 IC 50 value 110-324 nM, 30-to 50-fold selective for hKv1.5 over hERG, and poorly bioavailable in rat). 81, 82 ; and in dog stable drug plasma concentrations of approximately 0.3 mM selectively increased the AERP by 16%. 34 No effect on the QTc interval was observed at peak plasma concentrations of 1.8-2.0 mM and 20.3 mM in the dog and African green monkey, respectively. ISQ-1 terminated atrial flutter in 5/6 dogs at a mean intravenous dose of 2.5 mg/kg 6 0.5 mg/kg and selectively increased the AERP by 13%. 34 As with DPO-1, this study did not report individual dose group pharmacodynamic and pharmacokinetic information. ISQ-1 also terminated atrial fibrillation in 4/7 conscious dogs with underlying heart failure at all intravenous doses tested (0.03 to 1.0 mg/kg) without causing significant changes in the AERP (plasma concentration reached 1.3 mM). The reason for the lack of drug-related AERP changes in the heart-failure dogs is unknown. ISQ-1 is unlikely to enter clinical development because of its poor oral bioavailability. 37 However, both DPO-1 and ISQ-1 are Kv1.5 selective compounds that demonstrate atrial selectivity and efficacy in animal models without undesired ventricular effects.
The authors describe DPO-1 and ISQ-1 as investigational molecules that have contributed to Kv1.5 target validation.
Compound 19 has similar electrophysiologic properties to DPO-1 and ISQ-1 (hKv1.5 IC 50 value 60 nM); drug plasma concentration of approximately 5 mM increased the AERP and VERP by 30% and 35%, respectively, in rat, and drug plasma concentrations of ;0.1 mM selectively increased the AERP by 14% in dog. 81 It is important to note that Compound 19 has much improved oral bioavailability compared to ISQ-1. 81 Efficacy data in AF/AFl animal models and extensive cardiac ion channel selectivity data have not been reported for this compound. Based on the fact that AERP changes observed in dog were similar to DPO-1 and ISQ-1, one would reasonably expect this compound to be effective in similar arrhythmia models.
Triarylethanolamines
Triarylethanolamine (TAEA) is a potent inhibitor of hKv1.5 (IC 50 value 238 nM) 82 that terminated atrial fibrillation in 4/6 conscious dogs with underlying heart failure at all intravenous doses tested (0.01 to 0.3 mg/kg). Like ISQ-1, TAEA (drug plasma levels up to 2 mM) did not produce any detectable changes in the AERP in heart-failure dogs. In normal dogs, significant AERP increases were observed at 4-fold lower drug plasma levels. 82 
Diisopropylamides
Compound 10 is a potent inhibitor of hKv1.5 (IC 50 value 150 nM) that selectively increased dog AERP by 15% (plasma concentration 20 nM). 83 Efficacy data in clinically relevant animal models, pharmacokinetic data (oral bioavailability, half-life), and noncardiac safety data have not been reported for this compound.
In summary, DPO-1, TAEA, and Compound 10 are attractive development candidates if orally bioavailable, and Compound 19 is an attractive development candidate if efficacy is demonstrated in AF models. Taken together, the data presented for these compounds provide good evidence for the potential of selective Kv1.5 inhibitors to be safe and effective in the treatment of AF.
Procter and Gamble
Procter and Gamble have developed several novel Kv1.5 inhibitors from multiple chemical series that include triazoles, tetrahydroindolone-derived semicarbazones, tetrahydroindolone-derived carbamates, and tetrazoles.
2,4 Disubstituted 1,2,3-Triazoles
Compound 1f is a potent inhibitor of hKv1.5 (IC 50 value 294 nM) that is selective for Kv1.5 over hERG (170-fold) and L-type calcium currents (88-fold) and at 30mg/kg (intravenous administration) selectively increased pig AERP by 12%. 84 
Tetrahydroindolone-Derived Semicarbazones
Compound 8i is a potent inhibitor of hKv1.5 (IC 50 value 130 nM) that at 10 mg/kg (intravenous administration) selectively increased the pig AERP by 28%. 85 
Tetrahydroindolone-Derived Carbamates
Compound 29 is a potent inhibitor of hKv1.5 (IC 50 value 21 nM) that is at least 1000-fold selective for Kv1.5/ I Kur over hERG and L-type calcium currents. 86 
Tetrazole Derivatives
Compound 2f is a potent inhibitor of hKv1.5 (IC 50 value 330 nM) that is at least 50-fold selective for Kv1.5 over hERG and L-type calcium currents, and at 10 mg/kg (intravenous administration) selectively increased the pig AERP by 17%. 87 Efficacy data in clinically relevant atrial fibrillation animal models, pharmacokinetic data (oral bioavailability, half-life), and noncardiac safety data have not been reported for any of the preferred Kv1.5 inhibitors described by Procter & Gamble. Demonstration of oral bioavailability and efficacy in AF models will clearly need to be demonstrated before any of these compounds can advance toward development.
Wyeth
Two patents relating to 4-oxo-1,3,8-triaza-spiro [4, 5] 
XEN-D0101
XEN-D0101 inhibits hKv1.5 and human atrial I Kur with an IC 50 of 241 and 154 nM, respectively (data unpublished).
Intravenous doses of XEN-D0101 selectively increased the AERP in a rate-dependent and dose-dependent manner in normal dogs (eg, 3 mg/kg XEN-D0101 increased AERP 49% at 200 ms basic cycle length and by 22% at 360 ms basic cycle length 91 ), and in dogs with atrial tachycardia-induced electrical remodeling, XEN-D0101 selectively increased AERP by 25% at 1 mg/kg and 45% at 3 mg/kg. 92 XEN-D0101 did not increase the QTc interval at the highest dose in either dog AF model. XEN-D0101 significantly reduced the mean AF duration in normal dogs and atrial-tachypaced dogs and significantly reduced AF vulnerability in atrial tachypaced dogs. 91, 92 No ion channel selectivity, pharmacokinetic, or safety data have been reported for XEN-D0101.
CONCLUSIONS
This review highlights the wealth of new and novel Kv1.5 chemistry that is being developed by industry. However, the value of many of these new compounds is limited because these compounds have yet to demonstrate the desired druglike characteristics of Kv1.5 selectivity over other ion channels; atrial selectivity (in vivo); efficacy in clinically relevant AF animal models; oral bioavailability; safety in animals following repeat dosing; and, crucially, clinical efficacy and safety. As such, the accolade of ''first in class'' is still to be achieved. The most advanced Kv1.5 inhibitors reported are considered to be the following:
AVE0118, which reached Phase 2, although the results of this trial have not been reported. AVE0118 is a mixed ion channel inhibitor that is atrial selective in vivo and efficacious in multiple AF animal models. The physicochemical and pharmacokinetic properties of AVE0118 may limit the progression of this drug candidate for AF treatment. AVE1231 has similar pharmacology and pharmacodynamic effects to AVE0118 but has the advantage of being orally effective. This drug candidate is currently in Phase 1 for AF. The selection of a second clinical candidate, with similar mixed ion channel pharmacology (to AVE0118), is indicative of continuing confidence in target validity following a clinical efficacy Phase 2 trial. XEN-D0101 has entered Phase 1 and is being developed for the prevention of AF. Although XEN-D0101 has been shown to be atrial selective and efficacious in multiple dog AF models, its selectivity for Kv1.5 over noncardiac ion channels has not been reported. Icagen/BMS were planning to assess an unidentified Kv1.5 clinical development candidate in a Phase 1b pharmacodynamic study. However, in December 2005 Icagen/BMS announced discontinuation of the trial because of slow enrollment. The status of this development candidate and program is unknown. The fact that the drug development candidates described here have entered clinical development suggests that pharmacologic modulation of Kv1.5 in humans is widely seen to be an important candidate drug target. It remains to be demonstrated that Kv1.5 inhibitors are atrial selective and well-tolerated in a clinical setting. The recruitment criteria for clinical efficacy studies require careful consideration for Kv1.5 inhibitors.
Kv1.5 inhibitors have been shown to be very effective in animal models of AFl, vagal AF, sustained AF (following atrial high-rate pacing), and animals with AF and heart failure. In disease models and tissue a number of compounds display increased efficacy potentially as a result of ion channel remodeling in AF [93] [94] [95] [96] that may influence the functional role of Kv1.5 in atrial repolarization. The predictive value of these models is yet to be demonstrated. These observations should be taken into account when designing the recruitment criteria for Phase 2 clinical studies with Kv1.5 inhibitors.
